NCT03525522 is a NA clinical trial of Nd:YAG Laser in Lichen Sclerosus, sponsored by Dr Adolf Lukanovič.

Who is sponsoring NCT03525522?

NCT03525522 is sponsored by Dr Adolf Lukanovič.

What drugs are being tested in NCT03525522?

Interventions in NCT03525522: Nd:YAG Laser, Topical corticosteroid Diprosone.

What condition does NCT03525522 study?

NCT03525522 studies Lichen Sclerosus, Lichen Sclerosus Et Atrophicus.

Is NCT03525522 still recruiting?

NCT03525522 is currently status unknown. Last updated 15 May 2018.

Last reviewed 2018-05-15 · How we verify

NCT03525522

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus

Status unknown NA Last updated 15 May 2018

What this trial tests

NA trial testing Nd:YAG Laser in Lichen Sclerosus in 40 participants. Status unknown.

Timeline

28 January 2016

Primary endpoint
30 May 2018

30 May 2018

Quick facts

Lead sponsor	Dr Adolf Lukanovič
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	28 January 2016
Primary completion	30 May 2018
Estimated completion	30 May 2018

Drugs / interventions tested

Nd:YAG Laser
Topical corticosteroid Diprosone — full drug profile →

Conditions studied

Lichen Sclerosus — all drugs for Lichen Sclerosus →
Lichen Sclerosus Et Atrophicus — all drugs for Lichen Sclerosus Et Atrophicus →

Sponsor

Dr Adolf Lukanovič — full company profile →

Who can join

18 and older, female only, with Lichen Sclerosus or Lichen Sclerosus Et Atrophicus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the efficacy of Nd:Yttrium Aluminum Garnet Laser (Nd:YAG) Treatment of Lichen sclerosus in comparison with topical corticosteroid treatment. Half of participants will receive laser treatment and the other half corticosteroid treatment and the results will be followed for 6 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lichen sclerosus: The 2023 update.
De Luca DA, Papara C, Vorobyev A, Staiger H, et al · · 2023 · cited 94× · PMID 36873861 · DOI 10.3389/fmed.2023.1106318

Verify or expand the search:

Other trials of Nd:YAG Laser

Trials testing the same drug.

NCT06202651 — Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) Laser Treatment for Granular Corneal Dystrophy · NA · terminated
NCT05101603 — Effects of Nd:YAG Laser and Air Abrasive Combined Application in Patients With Periodontitis · NA · completed

Other recruiting trials for Lichen Sclerosus

Currently open trials in the same condition.

NCT06135402 — Comparison of Laser Treatment With Clobetasol Therapy in Patients With Lichen Sclerosus · NA · recruiting

Other Dr Adolf Lukanovič trials

Trials by the same sponsor.

NCT03296241 — Non-ablative Er:Yttrium Aluminum Garnet Laser for Stress Urinary Incontinence (SUI) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03525522 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr Adolf Lukanovič
Last refreshed: 15 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03525522.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing